Future possibilities are described in the field of pharmaceutical promotion. They include developments in media used, the targets for promotional messages, the appeals used in promotion, and the regulatory environment in which promotion occurs. A proposal is offered for consideration whereby effectiveness and efficiency in promotion are recognized and perhaps rewarded.
Get full access to this article
View all access options for this article.
References
1.
CarterJ.1991Rocky year for journals. Medical Marketing and Media26(3):72.
2.
DichterE.1968 Quoted in Mickey Smith, 67. Principles of Pharmaceutical Marketing. Philadelphia: Lea and Febiger.
3.
DonabedianA.1988Quality and cost: Choices and responsibilities. Inquiry25 (Spring): 90–49.
4.
FDC Reports1991aFDA will set up promotion abuse “Hotline.”FDC Reports53(17):1.
5.
FDC Reports1991bDrug promotion in “Guise of Scientific Exchange” is FDA's top priority for drug advertising division. FDC Reports53(25):4–5.
6.
HustonP.1991Surviving in a get-tough-on-promotion climate. Medical Marketing and Media26(6):40–42.
7.
JacobyJ.SmallC.1975The FDA approach to defining misleading advertising. Journal of Marketing39(10):65–73.
8.
SzeinbachS.JuergensJ.SmithM.FreemanR.1991Content analysis of pharmacoeconomic appeals in drug product advertisements. Journal of Research in Pharmaceutical Economics3(3):75–90.
